10-QPeriod: Q2 FY2005

QUEST DIAGNOSTICS INC Quarterly Report for Q2 Ended Jun 30, 2005

Filed July 28, 2005For Securities:DGX

Summary

Quest Diagnostics Inc. reported solid financial results for the second quarter and first half of 2005. Net revenues increased by 6.2% and 5.6% respectively, driven by higher testing volumes and an improved average revenue per requisition, largely due to a shift towards higher-value gene-based and esoteric testing. Profitability also saw a significant boost, with net income rising to $149 million for the quarter and $281 million year-to-date. This growth was supported by effective cost management, with selling, general, and administrative expenses decreasing as a percentage of revenue, and efficiencies gained from Six Sigma initiatives. The company also benefited from a lower interest expense following the redemption of its contingent convertible debentures. Financially, Quest Diagnostics demonstrated strong operating cash flow, which was used to fund capital expenditures, strategic acquisitions, and shareholder returns through dividends and share repurchases. The company ended the period with a healthy cash position and sufficient liquidity to support future growth.

Key Highlights

  • 1Net revenues increased 6.2% for the quarter and 5.6% for the six months ended June 30, 2005, compared to the prior year.
  • 2Net income grew to $149 million for the quarter and $281 million year-to-date, reflecting revenue growth and cost efficiencies.
  • 3Operating income margin improved to 19.0% for the quarter and 18.2% year-to-date, indicating enhanced profitability.
  • 4Average revenue per requisition increased by 1.2% and 1.7% respectively, driven by a shift to higher-value testing.
  • 5Operating cash flow was strong at $371 million for the first six months, supporting investing and financing activities.
  • 6The company completed the redemption of its contingent convertible debentures in January 2005, reducing interest expenses.
  • 7Capital expenditures for the six months were $124 million, with a small regional laboratory acquisition for $19 million.

Frequently Asked Questions

Revenue growth was driven by a combination of increased testing volumes (up 5.3% for the quarter) and an improved average revenue per requisition (up 1.2% for the quarter). This latter improvement was attributed to a shift in test mix towards higher-value esoteric and gene-based testing, as well as an increase in the number of tests ordered per requisition.

The company focused on efficiency initiatives like Six Sigma and standardization, which helped to offset increased costs associated with higher testing volumes and investments in sales, service, and IT. Selling, general, and administrative expenses, as a percentage of net revenues, decreased year-over-year, reflecting leveraged expense management and improved billing/collection processes through electronic systems.

Quest Diagnostics completed the redemption of its contingent convertible debentures in January 2005, which reduced its interest expense. The company also actively managed its debt, repaying $100 million under its senior unsecured revolving credit facility and utilizing borrowings under its secured receivables credit facility. Share repurchases and dividend payments continued as part of the company's capital allocation strategy.

Quest Diagnostics anticipates investing approximately $210 million to $230 million in capital expenditures during 2005, primarily for information technology, equipment, and facility upgrades. The company believes that cash from operations and its existing credit facilities provide sufficient liquidity to fund its operations, growth, and shareholder returns.